Innoviva Inc (INVA) Stock AnalysisINVAInnoviva Inc

Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. Its royalty portfolio includes respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, it is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. Its products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO, is for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in a Phase III clinical trial. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Innoviva Inc is a good buy right now due to its current price of $21.21, which is significantly below analyst price targets ranging from $34 to $42. The company has shown a strong 1-year change of +25.21% and a solid gross margin of 75.77%. However, the main risk is the recent Q2 loss of $83.4 million, which could impact investor confidence.